DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Japan Market Report for Uterine Fibroid Embolization Devices 2017 - MedCore" report to their offering.
In Japan, embolization procedures are projected to increase over the forecast period. In the field of gynecology, the embolization market covers polyvinyl alcohol (PVA) particles and microspheres as well as the percentage of procedures performed using gelatin sponge particles.
The momentum towards embolization procedures was in part triggered by the approval of microspheres to enter the Japan market in 2013. Specifically, Nippon Kayaku (authorized distributor for Merit Medical Systems, Inc.) received authorization for the distribution and marketing of Embosphere Microspheres and HepaSphere Microspheres in June 2013. Embosphere Microspheres are particularly valuable as the most clinically studied round embolic, [that] provide consistent and predictable results for effective embolization in the treatment of uterine fibroids, hypervascular tumors, and arteriovenous malformations. They are often referred to as the gold standard for UFE procedures.
The increase in procedure numbers is further fueling the growth in total unit sales. The market is comprised of microspheres and PVA particle sub-markets respectively. There is an overarching market shift towards microsphere particles both in Japan and globally. The volume of microspheres required per procedure is much higher than the volume of PVA particles required per procedure; 2.4 microspheres are used for every 1.4 PVA particles required per procedure. The shift towards microspheres has augmented unit sales, causing them to increase at an even faster rate than procedure numbers.
Key Topics Covered:
1. Research Methodology
2. Disease Overview
3. Product Assessment
4. Uterine Fibroid Embolization Device Market
For more information about this report visit http://www.researchandmarkets.com/research/xrhfpt/japan_market